Mesoblast Lead Product Shows Durable Long-Term Survival At Four Years In Kids With Graft Versus Host Disease

  • Mesoblast Limited MESO announced top-line long-term survival results for remestemcel-L from its Phase 3 trial (GVHD-001) in children with steroid-refractory acute graft-versus-host disease (SR-aGVHD). 
  • The results showed durable survival through 4 years of follow-up. 
  • These new long-term survival data are a key component of the company's BLA resubmission to the FDA for remestemcel-L in treating children with SR-aGVHD.
  • A four-year observational cohort survival study was performed on 51 evaluable children with SR-aGVHD.
  • Overall survival in the remestemcel-L cohort was 63% at one year, 51% at two years, and 49% at four years, with a median survival of 2 to 3 years. 
  • In recently published studies of children or adults with SR-aGVHD who received the best available therapy (BAT) or the only FDA-approved agent for adults, ruxolitinib, one-year survival was 40-49%, and two-year survival was 25%-38%, with median survival between 6.5 months and 11.1 months.
  • Mesoblast is working towards a potential U.S. approval for remestemcel-L and its first product launch in H1 CY2023.
  • Mesoblast is also developing remestemcel-L for chronic lower back pain due to degenerative disc disease.
  • It is working towards FDA clearance by year-end 2022 to commence the second Phase 3 trial.
  • Price Action: MESO shares traded 2.15% higher at $3.32 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!